DRUG PRIOR AUTHORIZATION COMMITTEE

December 16, 2004 TENTATIVE AGENDA

Welcome, Announcements and Introductions	Henry Petry Chairman
Minutes Review	Discussion/ Approval
Pharmacy Program/ Budget Update	George Oestreich/ Andrew Haslag
DUR Update	Tisha Pomering
Old Business Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	George Oestreich
New Business New Drug/Product Reviews a. Proposed Actions (See website and Attached Summary) i. Open Access ii. Clinical Edit/Step Therapy iii. Prior Authorization	George Oestreich/ Rhonda Driver
Proposed New Program Actions of Existing Products a. Clinical Edits i. Botox (edit changes) • Discussion • Public Hearing • Decision ii. Spiriva • Discussion • Public Hearing • Decision iii. Miralax (edit change) • Discussion • Public Hearing • Decision Iv. ADHD Therapy • Discussion • Public Hearing • Decision Iv. ADHD Therapy • Discussion • Public Hearing • Decision	George Oestreich/ Rhonda Driver
 b. Prior Authorization Edit Multiple Sclerosis Related Fatigue Discussion Public Hearing 	Edit (Provigil)
c. Preferred Drug List (PDL) i. Alpha-Glucosidase Inhibitors • Discussion • Public Hearing • Decision ii Biguanides • Discussion • Public Hearing • Decision iii. Biguanide Cominations	
	Pharmacy Program/ Budget Update DUR Update Discussion Public Hearing Discussion Public Hearing Decision Public Hearing Decision Public Hearing Decision Discussion Public Hearing Decision Decis

DiscussionPublic HearingDecision

iv. Meglitinides

- Discussion
- Hearing
- Decision

v. 2nd Generation Sulfoinylureas

- Discussion
- Public Hearing
- Decision

vi. Thiazolidinediones

- Discussion
- Public Hearing
- Decision

vii. Leukotriene Modifiers

- Discussion
- Public Hearing
- Decision

viii. Macrolides - Adult

- Discussion
- Public Hearing
- Decision

Ix. Macrolides - Pediatric

- Discussion
- Public Hearing
- Decision

x. Quinolones-Systemic

- Discussion
- Public Hearing
- Decision

d. <u>Discussion Items</u>

- i. Preferred Drug List / Process discussion
- ii. Therapeutic classes/Phase V

To be announced at the meeting.

1:45 LUNCH

2:00-2:10 Physician Inquiry Allison Lauf/Mary Heet
2:10-2:20 Drug Utilization Reports

Informal comments will be accepted from members of the audience at various points in the agenda.

Times noted are approximate, Agenda may move more quickly

Executive Session

2:20-2:25 Minutes Review Discussion/Approval
2:25-3:00 Case Reviews Allison Lauf/Mary Heet

NEXT MEETING: March 17, 2005